… by angiogenic growth factors, such as vascular endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF), and basic fibroblast growth factor (3). VEGF is the major factor …

… vascular endothelial growth factor (VEGF) -directed agents in renal cell carcinoma. Bevacizumab
… VEGFR-2, vascular endothelial growth factor receptor type 2; PI3K, phosphoinositide 3-…

… growth factor (VEGF) has been recognized as an important constituent of vascularization
and growth of solid … findings and clinical outcome in patients with renal cell carcinoma (RCC). …

… Cumulative evidence implicates the epidermal growth factor receptor (EGFR) as an important
therapeutic target in head and neck squamous cell carcinoma (HNSCC). The basis for the …

… patients, and squamous cell carcinomas) we were able to localize growth factor production
to specific epithelial cells (eg, basal, suprabasal epithelial cells, and tumor cells). The change …

… Summary Epidermal growth factor receptor (EGFR) content was determined by a radioligand
receptor assay in 140 primary laryngeal squamous cell carcinomas (median value of 8.4 …

… Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor
… growth factors: vascular endothelial growth factor (VEGF) and platelet-derived growth factor (…

… growth factor, platelet derived growth factor, epidermal growth factor and vascular endothelial
growth factor (VEGF), the most potent mitogenic factor [1] In RCC it has been shown that up…

… Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of
epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine …

… cells resulting in cellular proliferation. Elevated levels of epidermal growth factor (EGF) and
basic fibroblast growth factor (… .3, 4 Although these growth factors are known stimulators of …